U.S. Brain Tumor Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, and Others), By Indication (Pituitary, Meningioma, Glioma, and Others), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), and Country Forecast, 2023-2030

The U.S. brain tumor drugs market size was worth USD 736.9 million in 2022 and is projected to grow at a CAGR of 9.7% during the forecast period. 

The increasing incidence of new malignant and non-malignant brain tumor cases in the U.S. is one of the prevailing factors augmenting the demand for brain tumor drugs. Additionally, the shifting government's focus on promoting extensive research and development for developing new and promising drugs to cater to the rising patient population is likely to propel market growth.

For instance, according to the American Cancer Society, in 2022, the estimated number of new brain cancer cases was 25,050, an increase of 2.1% compared to 2021.

Moreover, rising awareness among the patient population and growing approval of cost-effective biosimilar drugs is anticipated to drive the U.S. brain tumor drugs market growth during the forecast period. The COVID-19 pandemic negatively impacted the market due to delayed diagnosis of new cases. Further, the manufacturers witnessed a decline in the sales of their cancer drugs due to disrupted demand and supply chains during the pandemic.

LATEST TRENDS

Technological Advancements in Brain Tumor Screening is a Prominent Market Trend 

Early diagnosis of brain tumors is challenging due to factors such as tumor size, location, and shape. Furthermore, the blood-brain barrier makes it difficult for some chemotherapy drugs and other ions to penetrate, thus making the treatment ineffective. To treat brain tumors at an early stage, proper diagnosis is essential.

Various companies operating in the market are investing extensively to launch new brain tumor detection tests and platforms to detect the condition initially and promote proper disease management. Thus, advancement in brain tumor detection is anticipated to increase the treatment rate among patients in the coming years.

For instance, in May 2023, Kiyatec, Inc., a precision oncology company, received funds from leading brain tumor patient organizations, the Brain Tumor Investment Fund and Sontag Innovation Fund, LLC, to support the commercialization of Kiyatec’s testing platform, 3D-Predict.

Moreover, researchers are trying to develop new drugs to increase the treatment efficacy among patients suffering from brain tumors.

For instance, MimiVax, LLC, a privately held clinical-stage biotechnology company located in New York, U.S., is developing an immunotherapeutic vaccine that targets a cell-survival protein, surviving found in 95% of glioblastomas.

DRIVING FACTORS

Presence of Potential Pipeline Drugs to Augment the Market Growth 

The growing prevalence of brain tumors and the rising diagnosis rate in the country present a large patient pool requiring treatment. Pharmaceutical manufacturers invest heavily in research & development activities to launch advanced drugs to meet the rising patient demand.

Moreover, increasing R&D funding by government agencies, rising clinical trials, and increasing collaboration among research institutes and pharmaceutical companies to develop and commercialize brain tumor drugs promote market growth.

For instance, in September 2022, researchers from the University of Cincinnati received a grant of USD 1.19 million from the National Institutes of Health to develop letrozole drug intended to treat glioblastoma.

Request a Free sample to learn more about this report.

According to the American Cancer Society, the estimated new brain cancer cases in males were higher than in females in the U.S. Furthermore, the estimated number of death cases in both genders was 18,280 in 2022.

RESTRAINING FACTORS

Exemption of Few Drugs from Medicare Reimbursement List to Hamper the Market Growth

Brain tumor treatment is expensive and often covered under Medicaid and Medicare, making it affordable for patients. However, the withdrawal of a few drugs from the Medicare programs makes the treatment using these drugs expensive and unaffordable for some patients. This also limits the preference of healthcare providers toward available brain tumor drugs for treatment.

For instance, in June 2021, NextSource Pharmaceuticals removed its brain tumor chemotherapy drug, Gleostine, from Medicare Part D, leaving fewer options for patients with approved and affordable chemotherapies. After exiting the federal discount program, the chemotherapy drug might cost the patients as much as USD 1,000 a capsule.

SEGMENTATION

By Therapy Analysis

Based on therapy, the market is categorized into targeted therapy, chemotherapy, immunotherapy, and others. The targeted therapy segment is anticipated to grow faster during the forecast period owing to the shifting patient preferences toward this therapy. Targeted therapy only destroys the cancerous cells without affecting the normal cells of the body and is safer than other therapies, thus raising its usage by healthcare professionals. Additionally, the launch of cost-effective targeted therapy biosimilars in the country is increasing the adoption of these drugs, thereby bolstering the targeted therapies segment growth in the forthcoming years.

For instance, in October 2022, Amneal Pharmaceuticals LLC launched Alymsys, an Avastin biosimilar. The launch of the drug provides easy access to affordable cancer therapeutics.

By Indication Analysis

By indication, the market is divided into meningioma, glioma, pituitary, and others. Meningioma dominated the market in 2022. The risk of developing meningioma increases with age and is common among adults 65 years and above. The country is experiencing a significant increase in its old-age population, which is likely to increase the adoption of brain tumor drugs. Furthermore, approval and launches of various drugs intended to treat meningioma support market growth.

For instance, according to the American Society of Clinical Oncology, meningioma accounted for 40% of the total brain tumor cases in the country. Moreover, as per the same source, approximately 42,260 meningioma cases will be diagnosed by the end of the year 2023.

By Distribution Channel Analysis

Based on distribution channel, the market is bifurcated into hospital pharmacies and retail & online pharmacies. Hospital pharmacies segment accounted for the largest U.S. brain tumor drugs market share in 2022. The segment's dominance is mainly attributed to the fact that brain cancer therapies are often prescribed after a thorough diagnosis, usually conducted in hospitals. Furthermore, these drugs usually require intravenous administration by experienced medical professionals, generally from hospitals. Due to these factors, cancer patients prefer hospital treatment, augmenting the segment growth in the coming years.

Furthermore, the gradual shift in patient preference toward online pharmacies due to less wait time, availability of big discounts, and others is expected to propel U.S. brain tumor drugs market growth in the coming years.

KEY INDUSTRY PLAYERS

The U.S. brain tumor drugs market is consolidated with a few leading players. Key players in the market include Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Amgen. The increasing focus by the players in seeking brain tumor drug approvals is the key factor contributing to their revenue growth. Moreover, the presence of a strong product portfolio, growing mergers, acquisitions, and partnerships to strengthen their market position, among others contribute to these companies' growth.

For instance, in June 2019, Pfizer received approval for Zirabev, a biosimilar to Roches’ Avastin intended for treating patients suffering from recurrent glioblastoma and other cancers.

Other companies, such as Amneal Pharmaceuticals, Nextsource Pharmaceuticals, and others, also operate in the market. The increasing focus of these players in launching new brain tumor drugs is anticipated to increase their market share.

LIST OF KEY COMPANIES PROFILED:

• F. Hoffmann-La Roche Ltd. (Switzerland)


• Novartis AG (Switzerland)


• Merck & Co. Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Amneal Pharmaceuticals LLC. (U.S.)


• Amgen Inc. (U.S.)


• NextSource Pharmaceuticals, LLC (U.S.)

KEY INDUSTRY DEVELOPMENTS: 

• March 2023 - Les Laboratoires Servier received the fast track designation from the U.S. FDA for its drug, “Vorasidenib” intended to treat recurrent or residual grade 2 IDH mutant diffuse glioma.


• March 2023 – Novartis AG received the U.S. FDA clearance for the drug combination, Tafinlar + Mekinist for pediatric patients suffering from low-grade glioma.


• March 2022 – The Ivy Brain Tumor Center commenced a 0/1b phase clinical trial to study the safety and efficacy of AstraZeneca’s drug AZD1390 developed for patients with recurrent grade IV gliomas.

REPORT COVERAGE

To gain extensive insights into the market, Request for Customization

The market research report provides a detailed market analysis. It focuses on key aspects such as an overview of technological advancements, prevalence of chronic diseases in the U.S, new product launches, key industry developments such as mergers, partnerships, and acquisitions, and the impact of COVID-19 on the market. Additionally, the report will provide key market trends, impact of COVID-19, and others. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that contributed to the growth of the market in recent years.

Report Scope & Segmentation